CRO Optimapharm enters the US market

| By | Clinical Trials, R&D
0
279

Optimapharm, a clinical research organization (CRO) headquartered in Croatia, announced the launch of the first U.S. office. The new office is located in New York and this will be a huge step for Optimapharm into the USA market.

Following the launch of the new office, Optimapharm appointed the Executive Vice President of USA Business Development, Mr. Charles Denis Maher.

Mr. Maher is a highly experienced Business Development professional with an impressive track record in the CRO and Pharma industry. Charles had worked for Sundia Meditech Company NY as Executive Director Of Business Development USA. He has twenty-five years in the CRO, full product development Phases I-IV biotech pharma marketplace. Within these roles he has provided leadership to develop business development teams that have annually achieved record growth. Prior to Sundia Meditech, Charles was EVP of Global Business Development for Azopharma CRO of Miramar, Florida and the company also surpassed all sales goals.

Also, the Optimapharm expanded of its office network and business development team and the appointment of Mr. Roy Ovel, an expert in business development with over 35 years’ experience in the CRO industry, as Chief Commercial Officer.

Earlier, this year Optimapharm acquired Czech clinical research company MKS Research.

SOURCE: optimapharm
SHARE
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.